Clostridium difficile infection and inflammatory bowel disease

Turkish Journal of Gastroenterology

Volumn 25, Issue 6, 2014, Pages 603-610

  Cojocariu, Camelia ^a,b   Stanciu, Carol ^b   Stoica, Oana ^a   Singeap, Ana Maria ^a,b   Sfarti, Catalin ^a,b   Girleanu, Irina ^a   Trifan, Anca ^a,b  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Laboratory of Immunology and Genetics Hospital St Spiridon   (Romania)

Author keywords

Clostridium difficile infection; Crohn's disease; Epidemiology; Inflammatory bowel disease; Risk factors; Ulcerative colitis

Indexed keywords

FIDAXOMICIN; FUSIDIC ACID; GLUTAMATE DEHYDROGENASE; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; QUINOLONE DERIVATIVE; RIFAXIMIN; TIGECYCLINE; VANCOMYCIN; WATER;

ANTIBIOTIC THERAPY; CELL CULTURE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; CROHN DISEASE; CYTOTOXICITY ASSAY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; ENZYME IMMUNOASSAY; HOSPITALIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; METALLIC TASTE; MORTALITY; NAUSEA; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; TREATMENT OUTCOME; ULCERATIVE COLITIS; FECAL MICROBIOTA TRANSPLANTATION; ILEAL POUCH-ANAL ANASTOMOSIS; ILEOSTOMY; INCIDENCE; PROCTOCOLECTOMY; PROPHYLAXIS; RECURRENT DISEASE; TREATMENT CONTRAINDICATION; CLOSTRIDIUM INFECTIONS; COMPLICATION; PEPTOCLOSTRIDIUM DIFFICILE;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84920383831     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.5152/tjg.2014.14054     Document Type: Review

References (50)

1. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 2010; 4: 409-16.
2. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-87.
3. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Impact of Clostridium difficile-Associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008; 29: 823-8.
4. Marwick CA, Yu N, Lockhart MC, et al. Community-Associated Clostridium difficile infection among older people in Tayside, Scotland, is associated with antibiotic exposure and care home residence: cohort study with nested case-control. J Antimicrob Chemother 2013; 68: 2927-33.
5. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365: 1693-1703.
6. Janarthanan S, Ditah I, Phil M, Adler GD, Ehrinpreis NM. Clostridium difficile-Associated diarrhea and proton pump inhibitor therapy. A Meta-Analysis. Am J Gastroenterol 2012; 107: 1001-10.
7. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
8. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 345-51.
9. Jen MH, Saxena S, Bottle A, Aylin P, Pollok RC. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 1322-31.
10. Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-Associated diarrhea in inflammatory bowel disease. J Crohns Colitis 2009; 3: 4-7.
11. Ricciardi JO, Ogilvie W Jr., Roberts PL, Marcello PW, Concannon TW, Baxter NN. Epidemiology of Clostridium difficile colitis in hospitalized patients with inflammatory bowel disease. Dis Col Rect 2009; 52; 40-5.
12. Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-50.
13. LaMont JT, Trnka YM. Therapeutic implications on Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 1980; 1: 381-3.
14. Navaneethan U, Venkatesh PGK, Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol 2010; 16: 4892-904.
15. Ananthakrishnan A, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010; 4: 589-600.
16. Saidel-Odes L, Borer A, Odes S. Clostridium difficile infection in patients with inflammatory bowel disease. Ann Gastroenterol 2011; 24: 263-70.
17. Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 428-41.
18. Sinh P, Barrett TA, Yun L. Clostridium difficile infection and inflammatory bowel disease: a review. Gastroenterol Res Pract 2011; 136064.
19. Reddy SS, Brandt LJ. Clostridium difficile infection and inflammatory bowel disease. J Clin Gastroenterol 2013; 47: 666-71.
20. Nitzan O, Elias M, Chazan B, Raz R, Saliba W. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroenterol 2013; 19: 7577-85.
21. Berg MA, Kelly PC, Farraye AF. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis 2013; 19: 194-204.
22. Rodemann JF, Dubberke ER, Reske KA, Seoda H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-44.
23. Reller ME, Alcabasa RC, Lema CA, et al. Comparision of two rapid assays for Clostridium difficile common antigen and a C difficile toxin A/B assay with the cell culture neutralization assay. Am J Clin Pathol 2010; 133: 107-9.
24. Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-Associated diarrhea, stratified by disease severity. Clinical Infectious Diseases 2007; 45: 302-7.
25. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012; 46: 145-9.
26. Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 976-83.
27. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010; 55: 415-20.
28. Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010; 340: 641-6.
29. Meyer AM, Ramzan NN, Loftus EV Jr, Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004; 38: 772-5.
30. Kaneko T, Matsuda R, Taguri M, et al. Clostridium difficile infection in patients with ulcerative colitis: investigations of risk factors and efficacy of antibiotics for steroid refractory patients. Clin Res Hepatol Gastroenterol 2011; 35: 315-20.
31. Kochhar R, Ayyagari A, Goenka MK, Dhali GK, Aggarwal R, Mehta SK. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol 1993; 16: 26-30.
32. Ott C, Girlich C, Klebl F, et al. Low risk of Clostridium difficile infections in hospitalized patients with inflammatory bowel disease in a German tertiary referral center. Digestion 2011; 84: 187-92.
33. Masclee GM, Penders J, Jonkers DM, Wolffs PF, Pierik MJ. Is Clostridium difficile associated with relapse of inflammatory bowel disease? Results from a retrospective and prospective cohort study in the Netherlands. Inflamm Bowel Dis 2013; 19: 2125-31.
34. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009; 104: 1162-9.
35. Kariv R, Navaneethan U, Venkatesh PG, Lopez R, Shen B. Impact of Clostridium difficile infection in patients with ulcerative colitis. J Crohns Colitis 2011; 5: 34-40.
36. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-64.
37. Ananthakrishnan AN, Oxford EC, Nguyen DD, Sauk J, Yajnik V, Xavier RJ. Genetic risk factors for Clostridium difficile infection in ulcerative colitis. Alimentary Pharmacology and Therapeutics 2013; 38: 522-30.
38. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36.
39. Barbut F, Decre D, Lalande V, et al. Clinical features of Clostridium difficile-Associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol 2005; 54: 181-5.
40. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl 1): S12-8.
41. Ben-Horin S, Margalit M, Bossuyt P, et al. European Crohns and Colitis Organization (ECCO). Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol 2009; 7: 981-7.
42. Cohen S, Gerding D, Johnson S, et al. Clinical practice guidance for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
43. Deshpande A, Pasupuleti V, Patel P, et al. Repeat stool testing for Clostridium difficile using enzyme immunoassay in patients with inflammatory bowel disease increases diagnostic yield. Curr Med Res Opin 2012; 28: 1553-60.
44. Kufelnicka AM, Kim TJ. Effective utilization of evolving methods for the laboratory diagnosis of Clostridium difficile infection. Clin Infect Dis 2011; 52: 1451-7.
45. Wang Y, Atreja A, Wu X, Lashner BA, Brzezinski A, Shen B. Similar outcomes of IBD in patients with Clostridium difficile infection detected by ELISA or PCR assay. Dig Dis Sci 2013; 58: 2308-13.
46. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-10.
47. Navaneethan U, Mukewar S, Venkatesh P G K, Lopez R, Shen B. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis 2012; 6: 330-6.
48. Murthy SK, Steinhart AH, Tinmouth J, Austin PC, Daneman N, Nguyen GC. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther 2012; 36: 1032-9.
49. Chiplunker A, Ananthakrishnan AN, Beaulieu DB, et al. Long-term impact of Clostridium difficile on inflammatory bowel disease. Gastroenterology 2009; 136 (Suppl 1): S1145.
50. Vonberg RP, Kuijper EJ, Wilcox MH, et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14 (Suppl 5): 2-20.